Evidence map›Paper›PMID 33917947›Full record

GuidelineCurrent oncology (Toronto, Ont.)2021

Patient and Patient Group Engagement in Cancer Clinical Trials: A Stakeholder Charter.

Stéphanie Michaud, Judy Needham, Stephen Sundquist, Dominique Johnson, Sabrina Hanna, Sharareh Hosseinzadeh, Vatche Bartekian, Patricia Steele, Sarita Benchimol, Nathalie Ross and 1 more

Abstract readGuideline
In one paragraph

Guideline in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stéphanie MichaudBioCanRx, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0001-7727-6070
Judy NeedhamCanadian Cancer Trials Group, Kingston, ON K7L 3N6, Canada.
Stephen SundquistCanadian Cancer Clinical Trials Network (3CTN), Toronto, ON M5G 0A3, Canada.
Dominique JohnsonMcPeak-Sirois Group for Clinical Research in Breast Cancer, Montreal, QC H2Y 2H2, Canada.
Sabrina HannaThe Cancer Collaborative, Montreal, QC H7W 0C3, Canada.
Sharareh HosseinzadehNovartis Pharma Canada, Dorval, QC H9S 1A9, Canada.
Vatche BartekianVantage BioTrials, Montreal, QC H4M 2N9, Canada.ORCID 0000-0002-5713-2317
Patricia SteeleColorectal Cancer Canada, Montreal, QC H3G 1J1, Canada.
Sarita BenchimolColorectal Cancer Canada, Montreal, QC H3G 1J1, Canada.
Nathalie RossNathalie Ross, Laval, QC H7L 4Z3, Canada.
Barry D SteinColorectal Cancer Canada, Montreal, QC H3G 1J1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background-to guide the implementation of patient centricity and engagement in cancer clinical trials (CTs) and to operationalize the Canadianized version of the Clinical Trials Transformation Initiative (C-CTTI) model, the development of a charter was identified by cancer CT stakeholders. Methods-the Canadian Cancer Trial Stakeholder Charter (the Charter) was initiated by Colorectal Cancer Canada (CCC) and developed via the-1-formation of an inclusive working group (WG) that drafted the document using recommendations collected during the development of the C-CTTI model; 2-socialization of the draft Charter to solicit feedback from cancer CT stakeholders, including those who attended the 2019 CCC Conference; and 3-incorporation of stakeholders' feedback and finalization of the Charter by the WG. Results-the Charter was built around five guiding principles-1-patient centricity; 2-commitment to education and training; 3-collaboration as equal and independent partners in research; 4-transparency and accountability; and 5-high standards in data collection integrity and honesty. These principles led to the Charter's five tenets, which stipulate stakeholder commitments, aiming to make CTs accessible to all patients, improve the design and implementation of CTs to benefit patients, expand recruitment and retention of patients in CTs, and further advance cancer research and treatment. Conclusions-the Charter is intended to integrate the patient voice into the Canadian cancer CT continuum. The next phases of the C-CTTI model include the adoption and implementation of the Charter, the establishment of a patient group training program, and the development of real-world evidence/real-world data methodologies.

Indexed as

NeoplasmsPatient ParticipationCanadaClinical Trials as TopicHumansCanadian Cancer Clinical Trialscancer patient groupsClinical Trials Transformation Initiativepatient centricitypatient engagementreal-world datareal-world evidencestakeholder charter

Identifiers

PMID33917947
PMCPMC8167642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.